IDEAYA Biosciences (IDYA) Total Non-Current Liabilities (2018 - 2021)

IDEAYA Biosciences has disclosed Total Non-Current Liabilities across 4 years of filings, most recently posting $81.8 million for Q3 2021.

• Total Non-Current Liabilities for Q3 2021 came in at $81.8 million, down 22.78% year-over-year; the trailing twelve-month figure through Sep 2021 was $81.8 million (down 22.78% YoY), and the FY2020 annual result was $100.0 million, up 695.6% from the prior year.
• Total Non-Current Liabilities came in at $81.8 million for Q3 2021 at IDEAYA Biosciences, down from $88.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $105.9 million in Q3 2020 to a low of $7.0 million in Q4 2018.
• The 4-year median for Total Non-Current Liabilities is $12.7 million (2019), against an average of $48.9 million.
• Across the five-year window, Total Non-Current Liabilities soared 792.3% in 2020 and decreased 22.78% in 2021, its largest moves.
• IDEAYA Biosciences' Total Non-Current Liabilities stood at $7.0 million in 2018, then surged by 79.91% to $12.6 million in 2019, then soared by 695.6% to $100.0 million in 2020, then dropped by 18.18% to $81.8 million in 2021.
• The last three Total Non-Current Liabilities figures came in at $81.8 million (Q3 2021), $88.1 million (Q2 2021), and $93.0 million (Q1 2021), per Business Quant data.